Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (vol 21, pg 1443, 2020)

Smith I; Robertson J.; Kilburn L.

首页> 外文期刊>The lancet oncology >Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (vol 21, pg 1443, 2020)

【24h】

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (vol 21, pg 1443, 2020)

机译：KI67的长期结果和预后价值围手术期内分泌治疗术后患者激素敏感性早期乳腺癌（诗意）：开放标签，多期，并行组，随机，第3阶段试验（Vol 21，PG 1443， 2020）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2020年第12期|共1页
作者
Smith I; Robertson J.; Kilburn L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial [J] . Smith Ian, Robertson John, Kilburn Lucy, The lancet oncology . 2020,第11期

机译：KI67在围手术期内分泌治疗后围手术期内分泌治疗后的长期结果和预后价值，激素敏感性早期乳腺癌（诗意）：开放标签，多期，并行组，随机，第3阶段试验
2. Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial (vol 21, pg 851, 2020) [J] . The lancet oncology . 2020,第7期

机译：开放后宫颈癌患者的生活质量与微创自由基子宫切除术（LACC）：多期，随机，开放标签，第3阶段，非劣级试验（Vol 21，PG 851,2020）的二次结果
3. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial (vol 21, pg 763, 2020) [J] . Tolaney S. M., Wardley A. M., Zambelli S. The lancet oncology . 2021,第3期

机译：ABEMACICLIB PLUS TRASTUZIMAB有或没有氟氯磺舒齐与曲妥珠单抗加上患有激素受体阳性的妇女的标准化疗（君主制）：随机开放标签，第2期试验（第21卷，PG 763 ，2020）
4. Accelerated versus standard epirubicin followed by cyclophosphamide methotrexate and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre phase 3 open-label randomised controlled trial [O] . David Cameron, James P Morden, Peter Canney, -1

机译：英国TACT2随机试验（CRUK / 05/19）：加速与标准表柔比星联合环磷酰胺甲氨蝶呤氟尿嘧啶或卡培他滨作为乳腺癌的辅助治疗：一项多中心3期开放标签随机对照试验
5. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial [O] . Ian Smith, John Robertson, Lucy Kilburn, 2020

机译：Ki67在围手术期内分泌治疗后的长期结果和预后价值在绝经后患者患有激素敏感的早期乳腺癌（诗意）：开放标签，多期，并联组，随机，第3阶段试验

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (vol 21, pg 1443, 2020)

著录项

相似文献

相关主题

期刊订阅